Shares of Lpath Inc. soared 31 percent Wednesday on the news that the San Diego-based firm signed a deal with Merck Serono, a subsidiary of Merck KGaA, to develop an anticancer antibody that could potentially garner $473 million for Lpath. (BioWorld Today) Read More